Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ODC1 | P11926 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479473 | 0.85 | PTPN1 (0.48) | BACE1PTPN1BCHEODC1ACHE | |
| SCHEMBL4479470 | 0.85 | PTPN1 (0.48) | BACE1PTPN1BCHEODC1ACHE | |
| SCHEMBL4485920 | 0.79 | MAOB (0.52) | CYP3A4HPGDNFKB1MEN1MAPT | |
| SCHEMBL4485916 | 0.79 | MAOB (0.52) | CYP3A4HPGDNFKB1MEN1MAPT | |
| SCHEMBL31021106 | 0.76 | TOP2A (0.53) | BACE1PTPN1BCHEODC1ACHE | |
| SCHEMBL31021107 | 0.76 | TOP2A (0.53) | BACE1PTPN1BCHEODC1ACHE | |
| SCHEMBL23965858 | 0.70 | TYR (0.53) | CYP19A1CHRNA7KDM4EALDH1A1GAA | |
| Angelmarin SCHEMBL30443353 | 0.68 | KDM4E (0.63) | ACHECYP19A1CYP3A4HPGDMAPT | |
| Angelmarin SCHEMBL29507688 | 0.68 | KDM4E (0.63) | ACHECYP19A1CYP3A4HPGDMAPT | |
| SCHEMBL29589724 | 0.66 | MAOB (0.52) | CYP3A4HPGDNFKB1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569530-B2 | Tannin-based antiproliferative pharmaceutical | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2026-03-10 | — | — | US | disclosed |
| US-12453799-B1 | Bioadhesive for medical and dental applications | IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) | 2025-10-28 | — | — | US | disclosed |
| US-20250249063-A1 | METHOD FOR TREATING ORAL CANCER | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2025-08-07 | — | — | US | disclosed |
| US-12318422-B2 | Tannin-based antiproliferative pharmaceutical | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2025-06-03 | — | — | US | disclosed |
| US-20240293492-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2024-09-05 | — | — | US | disclosed |
| US-20230210931-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-06 | — | — | US | disclosed |
| US-11376570-B1 | Method of forming copper oxide-on-copper nanomaterial catalyst mesh | KING ABDULAZIZ UNIVERSITY (SA) | 2022-07-05 | — | — | US | disclosed |
| US-11311492-B1 | Carbon nanomedicine with natural ligands | KING ABDULAZIZ UNIVERSITY (SA) | 2022-04-26 | — | — | US | disclosed |
| US-11234940-B1 | Method for making a noble metal nanomedicine | KING ABDULAZIZ UNIVERSITY (SA) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250249063-A1 | METHOD FOR TREATING ORAL CANCER | UGGT1, G6PD, UGT1A3 | BACE1 2460/4885PTPN1 978/4885BCHE 2703/4885 |
| US-20240293492-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | UGGT1, G6PD, UGDH | BACE1 2583/4885PTPN1 932/4885BCHE 3439/4885 |
| US-12569530-B2 | Tannin-based antiproliferative pharmaceutical | SLC2A3, SLC2A1, SLC2A8 | BACE1 1770/4885PTPN1 1000/4885BCHE 3188/4885 |
| US-20230210931-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | UGGT1, G6PD, UGDH | BACE1 2583/4885PTPN1 932/4885BCHE 3439/4885 |
| US-12318422-B2 | Tannin-based antiproliferative pharmaceutical | UGGT1, G6PD, UGDH | BACE1 2583/4885PTPN1 932/4885BCHE 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.